Pfizer (PFE) shares are up 20% year to date as the company emerges from its post-pandemic slump, though the article says the recovery is still at an early stage. Last quarter, revenue rose 3% and beat Wall Street expectations, helped by Eliquis and cancer drugs that offset lower COVID-19 product sales. Pfizer raised its full-year revenue guidance, reiterated adjusted EPS of $2.80 to $3 per share, and sees up to $6.7 billion in cost savings through 2029. The stock trades at about 10 times estimated 2026 earnings, while sell-side forecasts see 2027 EPS slipping from $2.96 to $2.88. Risks include clinical trial setbacks and the looming loss of patent protection for Eliquis and Ibrance.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
PFEpharmaceuticalsearningspatents
Open a keyword to see other news on the same topic.
Related news
- Why Merck Stock Flew Higher on Friday
Merck (MRK) shares climbed more than 2% on Friday, extending the positive reaction to its third-quarter results posted Thursday, while the S&P 500 fell a relatively steep 1.8%. Sales rose 5% to over $18 billion, driven by Keytruda, and non-GAAP net income fell 4% to nearly $6.2 billion, with both figures and its full-year 2026 guidance beating average analyst estimates. Two of the four big banks raised their price targets: Bank of America Securities to $165 from $163 and J.P. Morgan to $175 from $165, and both maintained their buy ratings. The author notes that Keytruda is approaching its patent cliff, but the pipeline offers room for another blockbuster, and the stock currently yields 2.3%.
- Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers Squibb's Growth Portfolio rose 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion, while shares were roughly flat in midday trading. Adjusted EPS fell 17% to $1.35 from $1.63, mainly because of acquired IPRD charges for upfront payments on licensed drug candidates, which cost $0.58 a share net of licensing income. The Legacy Portfolio rose 1%, helped by Eliquis outpacing generic erosion, though Eliquis faces patent expiration later this decade. The company raised its 2026 revenue guidance to $49.75 billion to $50.25 billion, and the adjusted EPS range was updated to absorb the charges. The article says investors should watch whether the Growth Portfolio holds double-digit growth and whether the licensed programs produce data that justifies their cost.
- Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You?
Pfizer (PFE) closed at $28.40 on October 12, returning almost 4% over six months versus 14% for the State Street SPDR S&P 500 ETF Trust and 21.25% for the Insider Monkey Billionaire Index, with a dividend yield near 6%. Trailing earnings of $0.77 per share produce a 226.32% payout ratio and a 36.73 trailing multiple, while a forward estimate of $2.90 gives a forward multiple of 9.76. The article says free cash flow is more than double net income and revenue grew last quarter, so the cash behind the dividend appears solid. However, net margin of 6.80% carries interest on $63.48 billion of debt, and the forward multiple only holds if earnings recover sharply, which the article suggests the 6% yield shows the market doubts. The article says net margin is the line to follow from here.
- A pharma giant is moving past one patent cliff — but another is already looming
Novartis says remibrutinib, its experimental multiple sclerosis (MS) drug, could generate more than $4 billion in peak annual sales, even though Barclays recently cut its peak sales forecast after late-stage trials showed it reduced relapses by less than analysts expected. The drug belongs to the BTK inhibitor class and aims to regulate immune cell activity rather than eliminate cells, unlike Kesimpta, an anti-CD20 antibody. University of Pennsylvania MS specialist Amit Bar-Or said its safety profile looks promising but it is unlikely to control relapses as effectively as Kesimpta, and its biggest market-expansion opportunity could come from trials in progressive MS, with a readout expected in 2031. Morningstar analyst Jay Lee said the $4 billion-plus forecast is 'within the realm of possibility' but not de-risked. Meanwhile, the market is already looking to the next patent cliff around 2032 for Kisqali and Kesimpta, whose expiries alone represent $18 billion in peak sales.
- Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Pfizer declared a $0.43 fourth-quarter dividend, its 352nd consecutive quarterly payout, which annualizes to $1.72 per share and a 5.9% yield, well above the roughly 1% average S&P 500 yield. The article asks whether the payout is sustainable, noting Pfizer halved its dividend in 2009 but has raised it every year since 2010. Eliquis and Xeljanz lose U.S. patent exclusivity this year, and Ibrance and Xtandi follow next year, which pressures revenue. Nurtec grew 18% in the second quarter, Lorbrena 37% and Padcev 23%, and free cash flow of about $11 billion over four quarters exceeded dividend payments by more than $1 billion. The author concludes that the dividend's durability depends on whether new pipeline drugs can replace the expiring ones.
- Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.
U.S. stocks keep hitting record highs, but the so-called Warren Buffett indicator, the total market cap of U.S. stocks relative to GDP, stands at a record 237.5%, far above the 138.5% peak during the early-2000 dot-com mania. The author argues the backdrop shapes how to invest rather than whether to invest, and recommends Pfizer (PFE) and Alphabet (GOOG, GOOGL) despite the warning. Pfizer's revenue has fallen from just over $100 billion in 2021 to around $60 billion, and patent expirations threaten roughly one-third of its drug portfolio, but Padcev sales reached $667 million in Q2, up 23%, and its forward dividend yield is nearly 6%. Alphabet is well positioned in AI as its Gemini chatbot outgrows competitors, Google handles nearly 90% of the world's web queries, and Android runs on 69% of the world's mobile devices.
Related markets
Latest news
- What the Big Banks' Third-Quarter Reports Say About Credit Card Borrowers
The article uses 30-day and 90-day delinquency rates and charge-off ratios from third-quarter reports at large banks to gauge credit card borrowers. Citigroup's 30-day delinquency rate was 1.16% for its own branded cards and 1.96% for private-label cards, both lower than a year earlier. JPMorgan reported a 30-day delinquency rate of 1.97% and a 90-day rate of 0.96%, while Bank of America posted net charge-offs of 3.22%. Capital One's 30-day delinquency rate of 3.72% was the highest in the group, though still down from a year ago, and its charge-off rate was 4.01%. The article says the data suggest consumers are holding up well despite inflation pressures.
- Microsoft Offers Voluntary Exits to 60,000 Workers. After 37 Years, He Risks Losing a 401(k) Tax Break With One IRA Rollover
Microsoft offered voluntary exits on October 26 to about 60,000 eligible employees in the U.S., Canada, India and Britain. Using a hypothetical 62-year-old with 37 years at the company, the article describes a $1.2 million 401(k) that includes $250,000 of Microsoft stock. Under net unrealized appreciation (NUA) rules, the example pays $42,400 in federal tax, versus $55,000 if the shares go into a traditional IRA, a $12,600 difference before other effects. The benefit requires distributing the whole balance from qualified plans within one tax year after a qualifying event, such as leaving the employer or reaching age 59½, and it is lost once shares move into an IRA. The article also notes that the timing of income and later sales can affect Medicare premium surcharges.
- 4 Words From Fed Chair Kevin Warsh Should Have Wall Street and Investors Quaking in Their Boots
The Fed held interest rates steady at the FOMC meeting on Oct. 28, but Chair Kevin Warsh said the central bank is 'working on' price stability as inflation remains above the 2% target. The article reads his remarks as implying further rate hikes, consistent with an ongoing tightening cycle. CME's FedWatch Tool puts a 65% probability that rates rise by at least 75 basis points, to 4.50%-4.75%, by Sept. 15, 2027. The article links inflation to tariffs, the Iran war and the AI build-out, noting that import prices for computer and electronic products rose 7.4% in the first 6 months of 2026.
- Alphabet (GOOGL) Stock Sees Fair Value Cut After Q3 Miss And Higher AI Spending
Alphabet's Fair Value Estimate was adjusted from US$429.46 to US$408.09, narrowing the implied upside in some analyst models. TD Cowen, BMO Capital and Oppenheimer highlighted AI and Google Cloud momentum, while Citi, JPMorgan, Piper Sandler, Deutsche Bank and BofA cut price targets after Search revenue growth came in below buy-side expectations, free cash flow softened and heavier AI and TPU capex weighed on sentiment. Updated assumptions include revenue growth moving from 21.31% to 22.16%, net profit margin from 30.54% to 29.44%, future P/E from 28.95x to 26.94x, and discount rate from 8.77% to 8.69%.
- 3 Capital Efficient Software Stocks For Steady Cash Flow
The article argues that as AI-heavy giants such as Amazon and Intel pour cash into data centers and chips, the market is punishing expensive or cash-hungry stocks, which may shift attention to quieter firms that generate steady free cash flow. It highlights 3 stocks from a high free-cash-flow screener, noting that the same screen found 32 more cash-generative businesses not covered in the piece. R Systems International (NSEI:RSYSTEMS) generates about ₹20.1b from IT services and ₹2.2b from BPO work, with a market value of roughly ₹29.7b, and its OptimaAI platform and AI-first delivery already influence an estimated 28% to 30% of revenue. Sonata Software (NSEI:SONATSOFTW), with a market value of about ₹61.9b, provides IT services, cloud and AI solutions, and the article says it avoids the heavy capital spending and balance sheet strain that worry some investors in hardware-intensive peers.
- Trumpflation Is Getting Worse and It Could Trigger a Wall Street Nightmare
The PCE price index rose 3.6% year over year in September, up from 3.4% in August, while core inflation accelerated to 3.1%, both above the Fed's 2% target. The article notes NY Fed research found businesses and consumers absorbed nearly 90% of the economic burden of tariffs imposed in 2025, but argues the Iran war now plays a larger role: Brent crude averaged $114 per barrel in September, up $23 from August, and gasoline jumped 9.1%, accounting for more than half the rise in consumer prices. At the October 28 meeting, the Fed held rates at 3.75% to 4.00% in a 10–2 vote, with two members wanting another quarter-point hike after September's unanimous increase. Real disposable income fell 0.3% in September even as nominal consumer spending rose 0.5%. The article warns that AI infrastructure spending could approach $1 trillion annually by 2027, and heavily indebted firms like CoreWeave, with about $35 billion in debt and $640 million in quarterly interest costs, could face higher financing costs if rates rise.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.